Private equity investment in Australian healthcare calls for specialist strategies, disciplined judgement and a nuanced view of scale, and legal advisers must adapt to keep pace.

In the first episode of our Clifford Chance Australia Private Capital Podcast, I spoke with Dr Michael Caristo on launching and operating a specialist private equity firm focused on healthcare investing. Beyond one firm’s approach, the discussion offers a useful lens on how private equity investors are navigating healthcare, and what that means for advisers.

In this blog, we examine the three key themes in more detail.

1. Specialisation is about how knowledge is built

Healthcare investing in Australia highlights the growing role of specialist strategies. The driver is less opportunity scarcity and more the complexity of the sector. Regulatory overlay, fragmented ownership and diverse business models limit straightforward pattern recognition.

Specialisation, however, does not mean arriving with complete expertise. It reflects a disciplined way of building it. That includes identifying where knowledge is incomplete, testing assumptions early and engaging closely with founders and sector participants.

For legal advisers, the implication is practical. Clients are often still forming their views during a transaction. Diligence and structuring advice can therefore shape the investment thesis, rather than simply confirm it. Deal processes tend to be more iterative as a result.

2. Scale must change the economics of the business

The discussion also challenges a familiar private equity narrative, namely that healthcare lends itself neatly to roll-up strategies, where investors buy and combine multiple smaller businesses in the expectation that scale alone will drive higher valuations.

While consolidation may support multiple expansion, the more important question is whether scale creates a genuine operational or commercial advantage.

In some areas, such as dental services or physiotherapy, scale can improve procurement terms, strengthen positioning with payors and support more consistent operations. In others, the benefits are less clear. Where scale does not meaningfully improve outcomes for patients, clinicians or counterparties, aggregation alone is unlikely to sustain value.

For lawyers, this distinction affects where to focus attention. Where scale underpins the thesis, integration risk, regulatory consistency and contractual frameworks with clinicians or payors become central. Where it does not, the resilience of the individual business is the key issue.

3. Investment discipline is designed to counter deal momentum

Private equity investing requires both conviction and control. Momentum is needed to advance a deal, but it also creates the risk of becoming too closely aligned with the asset or management narrative.

One response is to embed internal challenge into decision-making. Requiring independent conviction across decision-makers introduces discipline without necessarily slowing execution.

For advisers, this often explains why positions evolve during a transaction. Renewed questioning can reflect governance processes rather than inefficiency, and understanding that dynamic can help manage negotiations.

Taken together, these themes suggest that healthcare investing in Australia remains a developing but increasingly sophisticated market. For lawyers, the role extends beyond execution to engaging with how investment judgment is formed.

For those interested in how these dynamics are being tested in practice in the Australian market, my full discussion with Dr Michael Cristo can be accessed here.